Therapies aimed at increasing cDC1 abundance in tumors or facilitating their activation may therefore boost anti-tumor immunity and potentially increase the responsiveness of cancer patients to immunotherapy (Broz et al., 2014, Salmon et al., 2016, Spranger et al., 2017). This evidence concerns the gene MPPE1 and neoplasm.